Jiang Fang-yong, Sun Li-ping, Yang Jin
Department of Cardiology, Liuzhou People's Hospital, Fifth Affiliated Hospital of Guangxi Medical University, Guangxi.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011 Dec;31(12):1607-10.
To study the effects Xuezhikang (XZK) at different doses on inflammatory factors and blood lipids of patients suffering from acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI) and to discuss their safety.
Eighty ACS in patients receiving selective PCI treatment were randomly assigned to two groups, 40 cases in the normal dose group and 40 cases in the large dose XZK group. Besides routine therapy, all patients took XZK at the daily dose of 1.2 and 0. 6 g, twice daily. They started XZK from the very day of PCI operation. The therapeutic course for all was more than 8 weeks. The levels of high sensitivity C reactive protein (hs-CRP) and matrix metalloproteinase-9 (MMP-9) were detected in the two groups 1 week, 4 and 8 weeks after operation. The levels of TC, TG, HDL-C, LDL-C, changes of liver and renal functions were observed. The correlation between blood lipids and inflammatory factors were analyzed. The adverse reaction was recorded.
Compared with before medication, the serum levels of hs-CRP and MMP-9 decreased in the two groups 1 week, 4 and 8 weeks after operation, with statistical difference shown in the levels at the 8th week (P < 0.05). The decrease was more obvious in the large dose XZK group (P < 0.05). The LDL-C level obviously decreased in the two groups 4 and 8 weeks after operation (P < 0.05). The decrease was more obvious in the large dose XZK group at the 8th week (P < 0.05). The levels of hs-CRP and MMP-9 were positively correlated with the decrease degree of LDL-C in the large dose XZK group at the 8th week (r = 0.828, 0.922, P < 0.05). There was no significant difference in the occurrence of adverse reaction, hepatic or renal functions between the two groups.
XZK could lower the serum levels of hs-CRP, MMP-9, and LDL-C. More obvious effects were obtained in the large dose XZK group. The decrease degree of inflammatory factors was correlated with the decrease extent of blood lipids.
研究不同剂量血脂康（XZK）对急性冠状动脉综合征（ACS）患者经皮冠状动脉介入治疗（PCI）后炎症因子及血脂的影响，并探讨其安全性。
将80例接受选择性PCI治疗的ACS患者随机分为两组，正常剂量组40例，大剂量XZK组40例。所有患者在常规治疗基础上，分别服用每日剂量为1.2 g和0.6 g的血脂康，每日2次，自PCI手术当日开始服用，疗程均超过8周。术后1周、4周及8周检测两组患者高敏C反应蛋白（hs-CRP）和基质金属蛋白酶-9（MMP-9）水平，观察总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）水平及肝肾功能变化，分析血脂与炎症因子的相关性，并记录不良反应。
与用药前比较，两组患者术后1周、4周及8周血清hs-CRP和MMP-9水平均降低，第8周时差异有统计学意义（P<0.05），大剂量XZK组降低更明显（P<0.05）。术后4周及8周两组患者LDL-C水平均明显降低（P<0.05），第8周时大剂量XZK组降低更明显（P<0.05）。第8周时大剂量XZK组hs-CRP和MMP-9水平与LDL-C降低程度呈正相关（r=0.828，0.922，P<0.05）。两组患者不良反应发生情况及肝肾功能无明显差异。
血脂康可降低ACS患者PCI术后血清hs-CRP、MMP-9及LDL-C水平，大剂量XZK组效果更明显，炎症因子降低程度与血脂降低幅度相关。
